ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®GlobeNewsWire • 12/13/22
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/09/22
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common StockGlobeNewsWire • 12/07/22
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/22
ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022GlobeNewsWire • 11/02/22
ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NCGlobeNewsWire • 10/31/22
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/22
Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/03/22
ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022GlobeNewsWire • 08/03/22
ADMA Biologics, Inc.'s (ADMA) CEO Adam Grossman on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/22
ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022GlobeNewsWire • 05/04/22